Jacobs Levy Equity Management Inc. Buys 178,575 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

Jacobs Levy Equity Management Inc. increased its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 708,409 shares of the company's stock after buying an additional 178,575 shares during the period. Jacobs Levy Equity Management Inc. owned 0.86% of Editas Medicine worth $900,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Editas Medicine by 46.9% in the 3rd quarter. Barclays PLC now owns 178,507 shares of the company's stock valued at $607,000 after buying an additional 56,986 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Editas Medicine by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 267,758 shares of the company's stock valued at $340,000 after acquiring an additional 41,002 shares during the period. Thrive Wealth Management LLC bought a new position in Editas Medicine in the fourth quarter valued at about $36,000. SG Americas Securities LLC lifted its position in Editas Medicine by 103.7% during the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company's stock valued at $104,000 after purchasing an additional 41,573 shares during the period. Finally, Ieq Capital LLC acquired a new position in Editas Medicine during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 71.90% of the company's stock.

Editas Medicine Stock Up 10.1%

Shares of NASDAQ:EDIT traded up $0.15 during mid-day trading on Tuesday, reaching $1.64. 2,376,814 shares of the stock were exchanged, compared to its average volume of 2,571,232. The company has a market cap of $137.29 million, a P/E ratio of -0.64 and a beta of 2.15. The stock's 50 day simple moving average is $1.35 and its 200-day simple moving average is $1.63. Editas Medicine, Inc. has a one year low of $0.91 and a one year high of $6.22.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same period last year, the company earned ($76.00) earnings per share. Analysts anticipate that Editas Medicine, Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright started coverage on shares of Editas Medicine in a research report on Monday, April 28th. They set a "buy" rating and a $3.00 price target for the company. Robert W. Baird lowered their target price on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Cantor Fitzgerald raised Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Finally, StockNews.com raised Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, nine have given a hold rating, two have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $5.36.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.